The Trade Desk to Join the S&P 500 Index
The S&P 500® Index is widely regarded as the best single gauge of large-cap U.S. equities. The index includes 500 leading companies and covers approximately 80% of available market capitalization.
'This is a proud moment for everyone at The Trade Desk. Our inclusion in the S&P 500 is testament to the value and innovation we have delivered to the digital advertising industry since our founding, 16 years ago,' said Jeff Green, Co-Founder and CEO, The Trade Desk. 'This would not have been possible without the incredible work of every TTDer present and past, nor without the trust of every client and partner that has embraced the power of programmatic and the importance of objectivity.'
About The Trade Desk
The Trade Desk™ is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize digital advertising campaigns across ad formats and devices. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across North America, Europe, and Asia Pacific. To learn more, visit thetradedesk.com or follow us on Facebook, Twitter, and LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Pagaya Technologies (PGY) Soars 25.37% as Preliminary Q2 Results Suggest Exceeding Income Guidance
We recently published . Pagaya Technologies Ltd. (NASDAQ:PGY) is one of the top-performing companies on Thursday. Pagaya Technologies jumped by 25.37 percent on Thursday to end at $29.50 apiece following the preliminary results of its second quarter earnings performance that saw the company exceed its net income guidance. In a statement, Pagaya Technologies Ltd. (NASDAQ:PGY) said that it was expecting to announce $17 million in net income during the second quarter of the year, or 70 percent higher than the high-end range of its $0-$10 million guidance previously. Revenues were also expected to hit $326 million, or 5-12 percent higher than the $290 million to $310 million guidance prior. A shot of a financial trader's hands pressing buttons rapidly on a trading terminal. Pagaya Technologies Ltd. (NASDAQ:PGY) said it is finalizing the results of its earnings performance, with official data set to be released on August 7, 2025. 'Our second-quarter results reflect continued strong execution across our network, with a focus on consistent and profitable growth,' said Pagaya Technologies Ltd. (NASDAQ:PGY) CFO Evangelos Perros. While we acknowledge the potential of PGY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring
We recently published . Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at $21.97 apiece following announcements that it would shift its focus to high-impact programs as part of a corporate restructuring plan ultimately aimed at meeting financial obligations due in the next two years. In a statement, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said it was targeting $400 million in cost-saving measures annually through reducing operating expenses and laying off 500 jobs, or 36 percent of its workforce. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. The restructuring followed concerns on its Elevidys drug after the death of two patients from acute liver failure tied to taking the treatment. The incident triggered an investigation by the Food and Drug Administration (FDA) last month, with the watchdog noting that it was evaluating the need for further regulatory actions. According to Sarepta Therapeutics, Inc. (NASDAQ:SRPT), preliminary financial results of its second quarter performance saw Elevidys raking in $282 million in revenues. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
S&P/TSX composite down in late-morning trading, U.S. stock markets also lower
TORONTO — Losses in industrial and telecommunication stocks weighed on the Toronto market as Canada's main stock index fell in late-morning trading, while U.S. stock markets also pulled back. The S&P/TSX composite index was down 78.55 points at 27,308.38. In New York, the Dow Jones industrial average was down 149.30 points at 44,335.19. The S&P 500 index was down 3.89 points at 6,293.47, while the Nasdaq composite was down 15.60 points at 20,870.05. The Canadian dollar traded for 72.89 cents US compared with 72.71 cents US on Thursday. The September crude oil contract was up 78 cents US at US$67.01 per barrel. The August gold contract was up US$14.80 at US$3,360.10 an ounce. This report by The Canadian Press was first published July 18, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Sign in to access your portfolio
